CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 58, Issue 3, 1999, Pages 182-185

  Kortunay, Selim ^a   Bozkurt, Atila ^b   Bathum, Lise ^a   Basci, Nursabah E ^c   Çalgüneri, Meral ^a   Brøsen, Kim ^a   Ogz Kayaalp, S ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MEPHENYTOIN;

ADULT; AEROBIC METABOLISM; ARTICLE; BLOOD SAMPLING; CONNECTIVE TISSUE DISEASE; ENZYME METABOLISM; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; OLIGONUCLEOTIDE PROBE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0032908379     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.3.182     Document Type: Article

References (29)

1. Young RL, Johnson KJ, Richardson EC. Biology of disease: new concepts in the pathogenesis of drug-induced lupus. Lab Invest 1995;73:746-59.
2. Uetrecht JP, Woosley RL. Acetylator phenotype and lupus erythematosus. Clin Pharmacokinet 1981;6:118-34.
3. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39: 533-7.
4. Brosen K, Skjelbo E, Flacks H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1995;36:105-8.
5. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin, a new drug hydroxylation polymorphism in man. Eur J Pharmacol 1984;26:753-9.
6. Bertilsson L, Kalow \V. \Vhy are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations? Clin Pharmacol Ther 1993;53:608-10.
7. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckemidge AM. The activation of the biguanid antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism- a panel study. Br ] Clin Pharmacol 1991;31:689-92.
8. Balain JD, Sukhova N, Harris J\V, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. Clin Pharmacol Ther 1995;57:662-9.
9. Chang M, Dahl AI, Tybring G, Götharson E, Bertilsson L. Use of omeprazole as a probe drug for CYP2C19 phenorype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 1995;5:358-63.
10. deMorais SMF, \Vilkinson GR, Blaisdell J, Nakamura K, Meyer UR, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;22:15419-22.
11. deMorais SMF, Grant R\V, Blaisdell J, Meyer UA, Nakamura K, Goldstein J. Identification of a new genetic defect for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
12. Xiao Z, Goldstein JA, Xie H, Blaisdell J, \Vang \V, Jiang C, et a!. Differences in the incidence of the CYP2CI9 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997;281: 604-9.
13. Brøsen K, deMorais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995;5:312-17.
14. Baer AN, McAllister CB, Wilkinson GR, \Voosley RL, Pincus T. Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum 1986;29:843-9.
15. Beyeler C, Armstrong M, Bird HA, Idle JR, Daly AK. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 1996;55:66-8.
16. May DG, Black CM, Olsen NJ, Csuka ME, Tanner SB, Bellino L, et al. Scleroderma is associated with differences in individual routes of drug metabolism: A study with dapsone, debrisoquine, and mephenytoin. Clin Pharmacol Ther 1990;48:286-95.
17. Beyeler C, Daly AK, Armstrong M, Astbury C, Bird HA, Idle JR. Phenotype/genotype relationships for the cytochrome P450 CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.] Rheumatol 1994;21: 1034-9.
18. Lahha RG, Bradloiv HL, Kunkel HG, Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum 1979;22:1195-8.
19. Lahita R G, Bradlow H L, Fishman J. Increased 16-α-hydroxylation of estradiol in systemic lupus erythematosus. J CHn Endocrinol Metab 1981;53:174-8.
20. Lahita RG, Kunkel HG, Bradlow HL. Increased oxidation of testosterone in systemic lupus erythematosus. Arthritis Rheum 1983;26:1517-21.
21. Drayer DE, Lorenzo B, Lahita RG, Robbins \VC, Reidenberg AIM. Microsomal hydroxylation as measured by pentobarbital elimination in patients with idiopathic systemic lupus erythematosus. Clin Pharmacol Ther 1982; 32:195-200.
22. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 reused criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
23. Sanz E J, Villen T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine. Clin Pharmacol Ther 1989;45:495-9.
24. Bathum L, Hansen TS, Horder M, Brosen K. A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2 and CYP2C19*3 allele involving time resolved fluorometry. Ther Drug Monit 1998;20:l-6.
25. Basci NE, Brosen K, Bozkurt A, Isimer A, Sayal A, Kayaalp SO. S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphism in a Turkish population. Br J Clin Pharmacol 1994,38:463-5.
26. Basci NE, Bozkurt A, Kortunay S, Sayal A, Isimer A, Kayaalp SO. Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. Br J Clin Pharmacol 1996;42:771-3.
27. Kortunay S, Basci NE, Bozkurt A, Kayaalp SO, Sayal A, Isimer A. The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism. Eur J Clin Pharmacol 1997;53:261-4.
28. Drohse A, Bathum L, Brosen K, Gram LF. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol 1989;27:620-5.
29. Hockhart DA, Clauw DJ, Sale EB, Hewett J, \Voosley RL. Pharmacogenetic characteristic of the eosinophilia-myalgia syndrome. Clin Pharmacol Ther 1994;56:398-405.